Palisade Bio (PALI) Expected to Announce Quarterly Earnings on Monday

Palisade Bio (NASDAQ:PALI) will likely be posting its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:00 PM ET.

Palisade Bio Trading Down 4.4%

NASDAQ PALI opened at $1.94 on Monday. The company has a market cap of $289.06 million, a price-to-earnings ratio of -0.92 and a beta of 1.53. The company has a 50 day moving average of $1.77 and a 200-day moving average of $1.67. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.64.

Wall Street Analysts Forecast Growth

PALI has been the topic of a number of recent research reports. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday, January 22nd. Piper Sandler started coverage on Palisade Bio in a report on Monday, December 29th. They set an “overweight” rating and a $25.00 target price on the stock. Clear Str upgraded Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. Finally, Stifel Nicolaus assumed coverage on Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

Institutional Investors Weigh In On Palisade Bio

Several hedge funds have recently added to or reduced their stakes in PALI. Janus Henderson Group PLC bought a new stake in Palisade Bio during the 4th quarter worth approximately $24,822,000. RA Capital Management L.P. bought a new position in shares of Palisade Bio during the fourth quarter valued at $16,742,000. Franklin Resources Inc. bought a new position in shares of Palisade Bio during the fourth quarter valued at $11,968,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Palisade Bio during the fourth quarter worth $10,575,000. Finally, Squadron Capital Management LLC acquired a new position in shares of Palisade Bio during the fourth quarter worth $10,575,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.